(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of -6.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Xencor's revenue in 2026 is $104,973,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $11,498,009,312, with the lowest XNCR revenue forecast at $4,517,712,402, and the highest XNCR revenue forecast at $15,598,599,157. On average, 16 Wall Street analysts forecast XNCR's revenue for 2027 to be $6,977,248,421, with the lowest XNCR revenue forecast at $2,987,519,491, and the highest XNCR revenue forecast at $18,308,036,943.
In 2028, XNCR is forecast to generate $7,204,398,049 in revenue, with the lowest revenue forecast at $3,060,385,821 and the highest revenue forecast at $26,427,427,896.